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Abstract
Background: A village-randomized trial of a seven-valent pneumococcal-conjugate-vaccine (PCV-7) conducted in rural
Gambia showed a decrease of vaccine-type (VT) and a non-significant increase in non-vaccine-type (NVT) nasopharyngeal
carriage of pneumococci two years after vaccination. Here, we report findings four years after vaccination.
Methods: PCV-7 was given to all children below 30 months of age enrolled in the trial and to those born during its course in
all study villages. Villages were randomized (older children and adults) to receive PCV-7 (wholly vaccinated villages) or
serogroup-C-meningococcal-conjugate-vaccine (partly vaccinated villages). Cross-sectional surveys (CSS) to collect
nasopharyngeal swabs were conducted before and at various intervals after vaccination. Sixteen of these randomized
villages (8 wholly vaccinated and 8 partly vaccinated) participated in a CSS conducted four years after vaccination started.
Results: Four years after vaccination, the prevalence of VT pneumococcal carriage was slightly higher in partly than in
wholly vaccinated villages [6.4% versus 3.9% (p= 0.120)] compared to 24.4% in the pre-vaccination CSS (p,0.001).
Prevalence of NVT four years after vaccination was similar between study groups [32.7% versus 29.8% (p = 0.392),
respectively] compared to 51.1% in the pre-vaccination CSS (p,0.001). Four years after vaccination started, lower
prevalence of serotype 6A was detected in wholly vaccinated than in partly vaccinated villages (1.6% versus 3.5%, p = 0.093)
whilst the prevalence of serotype 19A was similar between groups (2.9% versus 2.5%, p = 0.779). The most prevalent
serotype 19A clone was ST 847. The most prevalent serotype 6A clone before vaccination was ST3324 whilst after
vaccination ST913 and ST1737 predominated. Fourteen out of 26 STs detected among the serotype 6A isolates were new
while no new 19A serotype ST was found.
Conclusions: The decline in prevalence of VT pneumococci seen shortly after PCV-7 vaccination was sustained four years
later with only a small difference between study arms. No significant serotype replacement was detected.
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Introduction
The prevention of pneumococcal disease is a major, interna-
tional public health priority due to the high burden of disease and
associated mortality, especially in children in developing countries
[1]. The marked efficacy of pneumococcal conjugate vaccines
(PCVs) in preventing pneumococcal disease from serotypes
included in the vaccine (vaccine-serotypes or VT) occurs in large
part through reduction of nasopharyngeal carriage [2,3]. Because
children are the major drivers of pneumococcal transmission [4], it
is not surprising that after introduction of PCV vaccination in
children, reduction in both nasopharyngeal carriage and invasive
disease has been seen in older members of the vaccinated
community [2,5–9]. Some studies undertaken after the introduc-
tion of PCVs have shown an increase in both the incidence of
invasive disease and the prevalence of carriage caused by serotypes
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not included in the vaccine (non-vaccine-serotypes or NVT), the
phenomenon named serotype replacement [2,3,8,10–13]. Sero-
type replacement has also been observed in non-vaccinated older
members of vaccinated communities. However, the overall
incidence of invasive pneumococcal disease has decreased
following vaccination despite the emergence of serotype replace-
ment [8].
It is likely that PCV vaccination facilitates serotype replacement
by inducing a humoral and/or cellular immune response that
makes it more difficult for VT pneumococci to colonize the
nasopharynx, opening the way for colonization by NVT
pneumococci and, perhaps, by other bacteria. In countries where
PCV has been introduced into routine immunization programs,
immune pressure against VT pneumococci will increase gradually
as more vaccinated individuals enter the population. Determining
the consequence of this would require long-term longitudinal
studies. As an alternative, we had conducted a cluster randomized
trial in which the pneumococcal population of some villages was
exposed to maximum immune pressure by immunizing the whole
population with PCV-7 (wholly vaccinated villages) with the
primary objective of evaluating the effect on nasopharyngeal
carriage of pneumococci compared with that seen in other villages
where only children less than 30 months of age and newborns
were vaccinated (partially vaccinated villages). The prevalence of
carriage with VT pneumococci fell after vaccination in all age
groups in both study arms, with a more marked drop in villages
where the whole community had received PCV-7 [7]. There was
little variation in the prevalence of NVT carriage following
vaccine introduction [7].
In 2009, one year after the trial had finished, The Gambia
introduced PCV-7 into the Expanded Programme on Immuniza-
tion (EPI) and newborns in the study communities continued to
receive 3 doses of PCV-7 given at 2,3 and 4 months of age. In
October 2010, two years after the RCT had finished and 4 years
after vaccination started, we conducted a further cross-sectional
survey (CSS) to evaluate the long-term impact of PCV-7
vaccination on the prevalence of pneumococcal nasopharyngeal
carriage in wholly and partially vaccinated villages. At the time of
this survey, all children younger than 7 years of age had received
PCV-7 in both study arms. The primary objectives of this long-
term CSS were to evaluate the impact of PCV-7 on pneumococcal
prevalence and serotype distribution in partly and wholly
vaccinated villages four years after vaccine introduction. Addi-
tional objectives were to describe the population structure before
and after vaccination of two key pneumococcal serotypes not
present in PCV-7 that can be influenced by vaccination: i) serotype
6A, a serotype against which some cross protection might be seen
following vaccination with PCV-7, which contains a serogroup 6B
conjugate [14], and ii) serotype 19A, a serotype frequently
associated with serotype replacement) [12,13].
Materials and Methods
Study site
The study was carried out in the Sibanor area, Western Region,
The Gambia. Twenty-one of the 55 villages in the study area were
selected for inclusion in the initial trial with an overall population
of 5441 in June 2006. Demographic characteristics of the study
population have been described previously [15].
Study participants gave individual informed consent; parental
consent was obtained for children up to 16 years of age. Both the
initial trial and the long-term follow-up study were approved by
the joint MRC/Gambia Government Ethics Committee and by
the ethics committee of the London School of Hygiene & Tropical
Medicine. Conduct of the trial was guided by a Data Safety and
Monitoring Board [7].
Trial design and surveys
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
A village-randomized trial of the impact of PCV-7 on
pneumococcal nasopharyngeal carriage was conducted in 21
Gambian villages between 2006 and 2008, with a baseline CSS
conducted in 2003–2004 before vaccination started. Both vaccine
recipients and laboratory personnel were blinded to village
allocation.
Preparations for the study, study design, method of randomi-
zation and conduct of the CSS have been presented in detail
previously [7]. In brief, because the non-licensed PCV-9 (which
included serotypes 1 and 5 in addition to the PCV-7 serotypes) had
already been shown to be effective in young children in a
randomized controlled trial conducted in The Gambia trial [16], it
was considered unethical not to give PCV-7 to young children in
all the study villages. Therefore, all children in the trial aged
between 2 and 30 months at enrolment, the age group covered by
the PCV-9 trial [16], received PCV-7 as did any child born during
the period of the study. Village randomization was applied to
subjects above the age of 30 months (2.5 years of age) when
vaccination started. On the basis of their randomization group,
subjects above the age of 30 months received either one dose of
PCV-7 (PrevenarH, Pfizer) (11 wholly vaccinated villages) or one
dose of a meningococcal serogroup C conjugate vaccine
(MeningitecH, Pfizer) (10 partly vaccinated villages). The menin-
gococcal vaccine was given to ensure blinding and is not expected
to have had any effect on pneumococcal carriage.
Only individuals 2.5 years of age and above participated in the
CSS surveys. As part of the initial trial, CSS were conducted
before vaccination (Baseline CSS) and 4–6, 12 and 22 months
after vaccination (CSS-1 to CSS-3 respectively). During each CSS,
nasopharyngeal swabs were collected from approximately 1,200
randomly selected, age stratified subjects [7]. Because of an
azithromycin mass drug programme as part of the Gambian
National Trachoma Elimination campaign prior to the CSS
conducted 22 months after vaccination (CSS-3), only a smaller
number of subjects could be included in this survey and this lead to
a reduction in the mean age group. All samples included in the
analysis of CSS-3 were collected before the azithromycin
campaign started in any of the villages included in this survey.
The main study ended in August 2008.
Cross-sectional survey 4 (CSS-4)
One year after the trial finished (August 2009), The Gambia
introduced PCV-7 into the EPI following the same schedule as
that used for young infants in the trial (vaccination at 2, 3 and 4
months of age). In addition, older children up to 2 years of age
were offered 1 dose of the vaccine.
Approximately 50 months after trial vaccination started and 15
months after national immunization with PCV-7 commenced, a
follow-up CSS survey was conducted in 16 of the 21 original study
villages: four villages were excluded as a consequence of
participation in the azithromycin mass treatment campaign (3
months before the CSS started) and the fifth village, the smallest in
the initial trial, declined to participate in the new survey. A
nasopharyngeal swab (NPS) was collected from 800 age-stratified,
randomly selected subjects during a one-month period (Septem-
ber–October 2010). Because the last update of the census had been
conducted two years before, all individuals who subsequently
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moved into the study area were not included in the randomization
and, as in the previous surveys, children younger than 2 years of
age were not included as all had received PCV-7 [7].
Sample handling
Sample handing and laboratory methods were similar in all the
CSS surveys. NPS were collected, using a calcium alginate swab,
from the posterior wall of the nasopharynx and immediately
inoculated into vials containing skim milk-tryptone-glucose-glyc-
erol (STGG) transport medium. Vials were placed in a cold box
before transfer to the Medical Research Council Laboratories at
Fajara within eight hours of collection and vials were stored at
270uC prior to analysis [17].
Laboratory methods
Microbiology. 10 mL of thawed, inoculated STGG medium
were plated onto a gentamicin blood agar plate and incubated for
18–24 hours at 35uC in 5% CO2. Pneumococcal identification
was based on colony morphology and conventional methods of
characterization (optochin susceptibility and bile solubility assays)
[15]. Serotyping was performed at the MRC Fajara Laboratories,
with capsular and factor typing sera (Statens Serum Institut,
Copenhagen, Denmark), using a modified latex agglutination
assay [18]. Equivocal results were confirmed by the Quellung
reaction.
Penicillin susceptibility. Serotype 6A and 19A isolates were
first screened using oxacillin disk diffusion. Oxacillin resistant
isolates that could be recovered from storage were subsequently
tested for penicillin susceptibility using E-test strips.
PCR. For all 6A/C serotypes detected by latex agglutination,
a PCR with specific primers for 6C was used to differentiate 6C
isolates from 6A [19,20].
Multilocus Sequence Typing (MLST). MLST was per-
formed on a restricted random selection of isolates of serotypes 6A
(n = 55; 1/3 of this number from the pre-vaccination survey and
2/3 from the post-vaccination surveys) and 19A (n= 43; 1/3 of
this number from the pre-vaccination survey and 2/3 from the
post-vaccination surveys)Samples from CSS-3 were not available.
Seven housekeeping genes were targeted: aroE, gdh, gki, recP, spi, xpt
and ddl. Amplification of all genes and separation of fragments was
carried out as described elsewhere [21].
Data management and statistical analysis
Pneumococcal serotypes were grouped as follows: (i) VT:
serotypes included in PCV-7 (4, 6B, 9V, 14, 18C, 19F, and 23F)
plus 6A which shows cross-protective immunity with serotype 6B;
and (ii) NVT: any other pneumococcal serotype including non-
typeable pneumococci. Individuals carrying both a VT and an
NVT at the same time were counted in both groups. The primary
outcomes of the study for each of the age groups were (i) the
prevalence of carriage of VT pneumococci and (ii) the prevalence
of carriage of NVT pneumococci.
Individuals were age grouped following widely used but
arbitrary age categories as follows: (i) young children: individuals
2.5 to less than 5 years of age; (ii) older children: individuals 5
years to less than 15 years of age; and (iii) adults: individuals aged
15 years and above. We excluded children less than 2.5 years as
they had been vaccinated in both study arms. Because children up
to 7 years had been vaccinated in both arms in CSS-4, we
compared groups in this last CSS considering also an age
subgroup - children 7 years to less than 15 years.
The sample size for the last study CSS was calculated so as to be
able to detect a 60% reduction in the prevalence of VT
pneumococcal carriage in each age group between wholly
vaccinated and partly vaccinated villages, with 80% power at a
two-sided 5% significance level [from 25% to 10% in the younger
and older children (n= 100 per arm and age group), and from
15% to 6% in adults (n = 200 per arm)]. Whilst the study was not
powered to detect effects on individual serotypes we carried out
exploratory analyses on serotypes 6A and 19A to look for possible
effects on these important serotypes and these are presented
alongside the main analyses. Given the relatively low power of the
study to detect effects on individual serotypes, observations relating
to 6A and 19A should be interpreted with caution.
Comparisons of quantitative measures were made using
Wilcoxon rank-sum tests. Comparisons of categorical variables
were made using Chi-square tests. For each of the surveys,
comparison of VT and NVT pneumococcal carriage between
study arms was done using mixed effects logistic regression with
village included as a random effect to allow for the cluster
randomized design. Mixed effects logistic regression was used to
compare carriage in different surveys within each study arm. The
analyses were carried out using Stata 11 (StataCorp); p-values less
than 0.05 were taken to indicate statistical significance.
Sequences were edited and complementary sense antisense
fragments were aligned using the Laser Gene DNA star 7.1
software. The sequences were submitted to the MLST database
website (www.mlst.net) and assigned to existing or novel allele or
sequence type numbers defined by the database. Sequence types
(STs) were analyzed for relatedness using Bionumerics software
(version 6.5; Applied Maths, Sint-Martens-Latem, Belgium).
Results
Study profile
Sixteen villages participated in the long-term survey (8 wholly
vaccinated and 8 partly vaccinated); 1624 NPS samples were
collected from residents of these 16 villages in the pre-vaccination
survey, 933, 956 and 361 NPS samples in the first three post-
vaccination surveys and 812 NPS samples in the long-term post-
vaccination survey reported in this paper (Figure 1). Table 1
provides a summary of the median age and sex of individuals
included in each of the surveys. Because of an azithromycin mass
drug programme prior to CSS-3 only a reduced sample of subjects
could be included in this survey and this lead to a reduction in the
mean age group.
Prevalence of pneumococcal carriage in the long-term
follow-up survey
Overall prevalence of pneumococcal carriage in CSS-4 was
35.5% (288/812), decreasing with increasing age (67.0% in young
children, 39.3% in older children and 17.6% in adults). Prevalence
of VT pneumococcal carriage was 5.0% (41/812) (11.0% among
young children, 7.9% among older children and 0.5% among
adults). The most common VT isolated was serotype 6A (n= 20),
representing 2.5% of all NPS samples; followed by serotypes 14
(n= 8) and 19F (n= 7). The overall prevalence of NVT carriage
was 31.2% (253/812) and also decreased with age (58.0% among
young children, 31.8% among older children and 17.3% among
adults). Approximately 10% of serotypes included in the NVT
group were non-typeable (n = 24). Serotype 19A (n= 22) was the
most prevalent NVT serotype, representing 2.7% of all NPS
samples, followed by serotypes 21 (n= 18) and serotype 35B
(n= 17). Serotype 6C isolates were not detected.
Long Term Impact of PCV-7 on Carriage
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Comparisons of wholly vaccinated versus partly
vaccinated villages
Prevalence of any pneumococcal carriage and NVT carriage
during CSS-4 was similar in wholly vaccinated and partly
vaccinated villages, except for a lower prevalence of any carriage
in vaccinated villages among older children (31% versus 47.6%,
p= 0.036). The prevalence of carriage of VT pneumococci was
lower, although not statistically significantly so, also among the
older children group (5–15 year old) resident in wholly vaccinated
villages compared to partly vaccinated villages (5.4% versus
10.7%, p= 0.161) (Table 2). This difference became more
remarkable, although still not statistically significant, when only
children aged 7-,15 years old were considered, excluding those
children in the partially vaccinated villages aged 5-,7 years old
who may have been vaccinated. In children in 7-,15 year old age
group resident in fully or partly vaccinated villages the prevalence
of pneumococcal carriage of any serotypes was 26.8% versus
46.2% (OR=0.43, p = 0.015) for all pneumococci, 1.4% versus
9.0% (OR=0.14, p= 0.074) for VT pneumococci and 25.4%
versus 38.5% (OR=0.54, p = 0.089) for NVT pneumococci.
The overall prevalence of serotype 6A was higher in partly
vaccinated versus wholly vaccinated villages (3.5% versus 1.6%,
p= 0.093). As a result, if we exclude serotype 6A in the VT goups,
the difference between wholly vaccinated and partly vaccinated
Figure 1. Trial profile. PCV-7: 7-valent pneumococcal conjugate vaccine; CSS-1: Cross-sectional 1; CSS-2: Cross-sectional 2; CSS-3: Cross-sectional 3;
CSS-4: Cross-sectional 4.
doi:10.1371/journal.pone.0072198.g001
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villages increases. The prevalence of serotype 19A was similar in
both groups of villages (2.9% versus 2.5%, p= 0.779) [Table 2].
Time trends in the prevalence of pneumococcal carriage
In partly vaccinated villages, prevalence of pneumococcal
carriage was significantly lower in CSS-4 compared to the baseline
CSS for overall pneumococcal carriage and VT carriage (all age
groups) and for NVT carriage (older children and adults). For
some serotypes there was a lower prevalence of carriage in CSS-4
compared to previous post-vaccination surveys (CSS-1 to 3)
[Figure 2, Table 3 and Table 4]. For serotype 6A, prevalence in
CSS-4 was lower than in the pre-vaccination survey (significantly
so for young children and adults p = 0.019 and p= 0.008
respectively). Serotype 19A prevalence was similar over the whole
observation period with a transitory increase in the wholly
vaccinated study arm in CSS-3, mostly driven by the youngest
age group that returned to the initial rate in CSS-4 (Figure 3,
Table 3 and Table 4).
Overall, the percentage of serotype 6A among VT isolates
increased over the study surveys (16.4% in the baseline CSS;
28.6%, 27.6% and 27.0% in CSS-1 to CSS-3 respectively; and
48.8% in CSS-4 –p,0.001). At the same time, the prevalence of
serotype 19A among NVT isolates also varied over the study
surveys (4.5% in the baseline CSS,1.8%, 2.8% and 11.5% in CSS-
1 to CSS-3; and 8.7% in CSS-4 – p,0.001).
Penicillin susceptibility for serotypes 6A and 19A isolates
Penicillin susceptibility was evaluated in 126/131 serotype 6A
isolates and all but one were susceptible. This isolate, which was
obtained in the baseline survey, had an intermediate level of
resistance. For serotype 19A, 90/96 isolates were tested five of
which were non-susceptible (intermediate level of resistance); one
of these isolates was obtained in the baseline survey and the
remaining four in CSS-4 (2 in the wholly vaccinated communities
and 2 in the partly vaccinated communities). The prevalence of
non-susceptibility among 19A isolates in CSS-4 was 18.2% (4/22).
Molecular analysis of serotypes 6A and 19A isolates
Serotype 6A genotyping. One hundred and thirty-one
serotype 6A isolates were obtained over the course of the five
surveys. Genotyping analysis was performed on 55 (42.0%) (16/65
from the pre-vaccination survey, 26/36 from CSS-1 and CSS-2;
Table 1. Age and sex distribution of participants in five CSS undertaken in partly and wholly vaccinated villages.
CSS survey Variable Partly vaccinated %(n) Wholly vaccinated %(n) p-value
Baseline Age group 0.160
(years) 2.5-,5 11.1 (77) 9.9(92)
5-,15 32.6(227) 37.1(344)
.=15 56.4(393) 53.0(491)
Median Age (years) 16.5 15.7 0.315
Sex Male 51.6 (360) 45.6(423) 0.016
CSS-1 Age group 0.242
(years) 2.5-,5 11.4 (48) 14.6(75)
5-,15 38.5 (162) 34.6(177)
.=15 50.1 (211) 50.8(260)
Median Age (years) 15.3 15.5 0.911
Sex Male 48.9(206) 45.1(231) 0.245
CSS-2 Age group 0.799
(years) 2.5-,5 12.0(55) 12.7(63)
5-,15 37.0(170) 35.0(174)
.=15 51.0(234) 52.3(260)
Median Age (years) 15.5 16.3 0.641
Sex Male 47.3(217) 48.9(243) 0.617
CSS-3 Age group 0.242
(years) 2.5-,5 20.1(31) 13.5(28)
5-,15 50.6(78) 55.6(115)
.=15 29.2(45) 30.9(64)
Median Age (years) 8.5 8.6 0.212
Sex Male 48.0(74) 48.3(100) 0.961
CSS-4 Age group 0.696
(years) 2.5-,5 23.6(88) 25.5(112)
5-,15 27.6(103) 25.3(111)
.=15 48.8(182) 49.2(216)
Median Age (years) 14.0 14.7 0.662
Sex Male 50.9(190) 51.7(227) 0.827
doi:10.1371/journal.pone.0072198.t001
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Table 2. Prevalence of nasopharyngeal carriage of any pneumococcus (Any type), vaccine serotypes (VT), non-vaccine serotypes
(NVT) and serotypes 6A and 19A detected during CSS-4 (four years after vaccination) in partly and wholly vaccinated villages by
age group.
Partly vaccinated Wholly vaccinated
Serotype Group
Age group
(years) % (n/N) % (n/N) OR (95% CI) p-value
Any Type 2.5-,5 67.0% (59/88) 67.0% (75/112) 1.12 (0.47, 2.66) 0.803
5-,15 47.6% (49/103) 31.5% (35/111) 0.47 (0.23, 0.95) 0.036
.=15 19.2% (35/182) 16.2% (35/216) 0.81 (0.48, 1.36) 0.430
All ages 38.3% (143/373) 33.0% (145/439) 0.79 (0.54, 1.16) 0.233
VT 2.5-,5 13.6% (12/88) 8.9% (10/112) 0.69 (0.20, 2.32) 0.547
5-,15 10.7% (11/103) 5.4% (6/111) 0.48 (0.17, 1.34) 0.161
.=15 0.5% (1/182) 0.5% (1/216) 0.84 (0.05,13.56) 0.903
All ages 6.4% (24/373) 3.9% (17/439) 0.59 (0.31, 1.15) 0.120
NVT 2.5-,5 55.7% (49/88) 59.8% (67/112) 1.19 (0.67, 2.09) 0.556
5-,15 37.9% (39/103) 26.1% (29/111) 0.56 (0.28, 1.10) 0.094
.=15 18.7% (34/182) 16.2% (35/216) 0.84 (0.50, 1.42) 0.516
All ages 32.7% (122/373) 29.8% (131/439) 0.87 (0.64, 1.19) 0.392
Serotype 6A (VT) 2.5-,5 6.8% (6/88) 3.6% (4/112) 0.51 (0.14, 1.85) 0.304
5-,15 5.8% (6/103) 2.7% (3/111) 0.45 (0.11, 1.84) 0.267
.=15 0.5% (1/182) 0.0% (0/216) 0.00 ------------ 0.998*
All ages 3.5% (13/373) 1.6% (7/439) 0.45 (0.18, 1.14) 0.093
Serotype 19A (NVT) 2.5-,5 8.0% (7/88) 4.5% (5/112) 0.55 (0.16, 1.85) 0.332
5-,15 1.9% (2/103) 5.4% (6/111) 2.74 (0.29,25.76) 0.378
.=15 1.1% (2/182) 0% (0/216) 0.00 ------------- 0.457*
All ages 2.9% (11/373) 2.5% (11/439) 0.86 (0.30, 2.48) 0.779
*p-values obtained using Fisher’s exact test.
doi:10.1371/journal.pone.0072198.t002
Figure 2. Prevalence of pneumococcal carriage of any serotype (Any), vaccine serotype (VT), and non-vaccine serotype (NVT) in
cross-sectional surveys before and after vaccination with PCV-7 stratified by age group and study arm (solid lines indicate partly
vaccinated villages and dashed lines indicate wholly vaccinated villages).
doi:10.1371/journal.pone.0072198.g002
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and 13/20 from CSS-4). Twenty-six STs were found, among
which 14 were new with one isolate each. The most prevalent
clone before vaccination was ST3324; after vaccination the most
prevalent clone was ST913 followed by ST1737, representing
respectively 10.9%, 14.5% and 12.7% of the analysed isolates
(Table 5). Only two of 14 new STs were found before vaccination,
Figure 3. Prevalence of pneumococcal carriage of serotypes 6A (VT group) and 19A (NVT group) in cross-sectional surveys before
and after vaccination with PCV-7 stratified by age group and study arm (solid lines indicate partly vaccinated villages and dashed
lines indicate wholly vaccinated villages).
doi:10.1371/journal.pone.0072198.g003
Table 3. Comparison of prevalence of nasopharyngeal carriage of any pneumococcal carriage (Any type), vaccine serotypes (VT),
non-vaccine serotypes (NVT) and serotypes 6A and 19A in different cross-sectional surveys in partly vaccinated villages.
CSS-4 vs Baseline CSS-4 vs CSS-1 CSS-4 vs CSS-2 CSS-4 vs CSS-3
Serotype group
Age
Group
(years) OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value
Any type 2.5-,5 0.18 (0.07,0.46) ,0.001 0.27 (0.10,0.71) 0.008 1.26 (0.61,2.60) 0.538 0.69 (0.25,1.89) 0.467
5-,15 0.15 (0.09,0.25) ,0.001 0.53 (0.32,0.88) 0.014 1.02 (0.62,1.67) 0.950 0.52 (0.28,0.97) 0.040
.= 15 0.154 (0.10,0.24) ,0.001 0.80 (0.49,1.31) 0.373 0.80 (0.50,1.30) 0.367 0.49 (0.24,1.02) 0.056
All ages 0.20 (0.15,0.26) ,0.001 0.76 (0.56,1.02) 0.071 1.11 (0.82,1.49) 0.494 0.60 (0.40,0.89) 0.011
VT 2.5-,5 0.15 (0.07,0.33) ,0.001 0.58 (0.23,1.48) 0.253 0.42 (0.18,1.01) 0.052 0.35 (0.12,1.03) 0.057
5-,15 0.21 (0.10,0.42) ,0.001 1.27 (0.54,2.99) 0.577 1.21 (0.53,2.76) 0.657 0.68 (0.28,1.63) 0.388
.= 15 0.02 (0.003,0.18) ,0.001 0.12 (0.01,0.96) 0.046 0.15 (0.02,1.23) 0.077 0.04 (0.01,0.37) 0.004
All ages 0.18 (0.11,0.28) ,0.001 0.85 (0.49,1.47) 0.558 0.79 (0.46,1.35) 0.383 0.42 (0.23,0.76) 0.004
NVT 2.5-,5 1.02 (0.55,1.89) 0.955 0.47 (0.22,1.01) 0.054 2.19 (1.09,4.40) 0.028 1.43 (0.60,3.41) 0.413
5-,15 0.42 (0.26,0.67) ,0.001 0.48 (0.29,0.80) 0.004 0.96 (0.58,1.59) 0.869 0.63 (0.35,1.14) 0.129
.= 15 0.29 (0.19,0.44) ,0.001 0.94 (0.57,1.56) 0.825 0.90 (0.55,1.48) 0.692 0.67 (0.31,1.43) 0.302
All ages 0.44 (0.33,0.58) ,0.001 0.75 (0.55,1.01) 0.055 1.18 (0.87,1.60) 0.274 0.78 (0.52,1.15) 0.211
Serotype 6A (VT) 2.5-,5 0.79 (0.24,2.62) 0.702 0.72 (0.19,2.77) 0.638 0.63 (0.18,2.23) 0.474 0.34 (0.08,1.47) 0.148
5-,15 3.61 (0.98,13.34) 0.054 9.86 (1.16,83.63) 0.036 2.59 (0.71,9.49) 0.150 4.85 (0.56,41.7) 0.151
.= 15 0.16 (0.02),1.29) 0.085 Infinite (---)a 0.463 0.60 (0.05,6.73) 0.678 0.21 (0.01,3.59) 0.283
All ages 1.10 (0.54, 2.22) 0.792 3.09 (1.09,8.76) 0.034 1.50 (0.66,3.40) 0.332 1.09 (0.40,2.95) 0.860
Serotype 19A (NVT) 2.5-,5 0.62 (0.22,1.80) 0.381 Infinite (---)a 0.051 4.28 (0.50,36.42) 0.183 0.58 (0.12,2.78) 0.499
5-,15 0.51 (0.11,2.46) 0.402 1.48 (0.20,10.73) 0.697 0.80 (0.14,4.48) 0.803 0.56 (0.09,3.45) 0.531
.= 15 1.03 (0.19,5.48) 0.968 Infinite (---)a 0.214 1.53 (0.21,11.13) 0.673 Infinite (---)a 1.000
All ages 0.83 (0.39,1.77) 0.637 6.22 (1.36,28.45) 0.018 1.90 (0.72,5.01) 0.192 0.99 (0.35,2.75) 0.983
aIt was not possible to fit the model.
OR’s were calculated ignoring clustering and p-values using Fisher’s exact test.
doi:10.1371/journal.pone.0072198.t003
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the rest were detected only after vaccination. Most of the new
genotypes clustered around ST1737 which was seen before and
after vaccination. ST919, ST3324 and ST1737 were more
commonly found in vaccinated than in control villages.
Serotype 19A genotyping. Ninety-six serotype 19A isolates
were obtained over the course of the five surveys. Forty-three were
randomly selected for genotyping (15/38 from the pre-vaccination
survey; 15/15 from CSS-1 and CSS-2; and 12/22 from CSS-4).
Fourteen STs of serotype 19A were described among these 43
isolates and none was new. ST847 was the most prevalent during
both the pre and post vaccination period, representing 58.1%
(n= 25) of all analyzed isolates (Table 6). All STs were equally
distributed between vaccinated and control villages except for
ST4029 which was more commonly found in control villages.
Discussion
To anticipate the potential long-term effects of the introduction
of PCV in sub-Saharan Africa, we conducted a novel CRT in
which several villages in rural Africa were exposed to maximum
immune pressure by vaccinating all residents with PCV-7 and
compared the prevalence of pneumococcal carriage in these
villages with that in villages where only children less than 30
months had been vaccinated [7]. The initial drop in the
prevalence of VT pneumococcal nasopharyngeal carriage ob-
served in all age groups early after vaccination in both wholly
vaccinated and partly vaccinated villages was attributed to the
herd effect of vaccine introduction in young children, whilst the
slightly greater drop observed in wholly vaccinated than in partly
vaccinated villages was attributed to the direct effect of the
vaccine.
Our analysis shows that more than four years after PCV-7
vaccination the overall prevalence of pneumococci was similar in
fully and partly vaccinated villages with a trend towards lower
prevalence among young children (5-,15 years age group) in the
wholly vaccinated communities. For the same age group, the
prevalence of VT pneumococcal carriage was lower in fully
vaccinated compared to partly vaccinated villages (5.4% versus
10.7%), although this difference was not statistically significant
(p = 0.161). However, in a sub-analysis, not defined in the original
statistical plan, undertaken in children aged 7-,15 years to
exclude any vaccinated children resident in the partly vaccinated
villages, the difference between groups became more remarkable
(1.4% versus 9.0%) with borderline statistical significance
(p = 0.074) suggesting that vaccination of a whole village had
provided some benefit to these older children. However, this later
finding needs to be treated with caution as it is based on an
analysis undertaken after the initial results had been obtained and
p-values had not been adjusted by the number of groups
compared. The time trend analysis showed a continuous decrease
of VT pneumococcal carriage and no increase in NVT prevalence
in both groups of villages. In contrast to what has been observed in
some other areas [22], VT have not been eliminated yet from the
study area and several more years of vaccination may be needed to
achieve this goal.
Table 4. Comparison of prevalence of nasopharyngeal carriage of any pneumococcal carriage (Any type), vaccine serotypes (VT),
non-vaccine serotypes (NVT) and serotypes 6A and 19A in different cross-sectional surveys in wholly vaccinated villages.
Serotype group
Age
group
(years) CSS-4 vs Baseline CSS-4 vs CSS-1 CSS-4 vs CSS-2 CSS-4 vs CSS-3
OR (95%CI) p-value OR 95%CI p-value OR (95%CI) p-value OR (95%CI) p-value
Any 2.5-,5 0.28 (0.13,0.58) 0.001 0.27 (0.12,0.61) 0.002 1.58 (0.83,3.01) 0.165 0.49 (0.18,1.37) 0.173
5-,15 0.07 (0.04,0.12) ,0.001 0.25 (0.15,0.41) ,0.001 0.55 (0.33,0.93) 0.024 0.21 (0.12,0.38) ,0.001
.= 15 0.16 (0.11,0.24) ,0.001 0.46 (0.29,0.73) 0.001 0.75 (0.47,1.20) 0.225 0.56 (0.29,1.09) 0.088
All ages 0.17 (0.13,0.22) ,0.001 0.46 (0.35,0.61) ,0.001 0.99 (0.74,1.32) 0.924 0.45 (0.31,0.64) ,0.001
VT 2.5-,5 0.08 (0.04,0.18) ,0.001 0.42 (0.18,1.02) 0.057 0.35 (0.14,0.85) 0.021 0.49(0.14,1.78) 0.280
5-,15 0.14 (0.06,0.33) ,0.001 0.70 (0.25,1.93) 0.489 2.80 (0.68,11.48) 0.154 0.91(0.29,2.81) 0.870
.= 15 0.03 (0.00,0.15) ,0.001 0.10 (0.00,0.66) 0.008 0.30 (0.01,3.04) 0.383 Inf (---)a 1.000
All ages 0.13 (0.07,0.21) ,0.001 0.49 (0.27,0.89) 0.019 0.90 (0.47,1.73) 0.75 0.84 (0.38,1.82) 0.653
NVT 2.5-,5 1.37 (0.78,2.38) 0.272 0.66 (0.35,1.22) 0.184 2.27 (1.21,4.26) 0.011 0.81 (0.33,1.95) 0.638
5-,15 0.19 (0.12,0.31) ,0.001 0.25 (0.15,0.43) ,0.001 0.48 (0.2830.82) 0.007 0.22 (0.12,0.39) ,0.001
.= 15 0.28 (0.19,0.42) ,0.001 0.55 (0.35,0.87) 0.010 0.80 (0.49,1.28) 0.346 0.56 (0.29,1.09) 0.087
All ages 0.38 (0.29,0.49) ,0.001 0.53 (0.40,0.70) ,0.001 0.98 (0.73,1.31) 0.908 0.47 (0.33,0.67) ,0.001
Serotype 6A (VT) 2.5-,5 0.25 (0.08,0.80) 0.019 0.51 (0.13,1.97) 0.330 0.55 (0.13,2.28) 0.410 0.43 (0.07,2.59) 0.359
5-,15 0.51 (0.14,1.82) 0.300 1.49 (0.29,7.63) 0.635 4.54 (0.46,45.05) 0.196 1.51 (0.24,9.37) 0.656
.= 15 0.00 (0.00,0.57) 0.008 0.00 (0.00,0.65) 0.018 -b - -b -
All ages 0.32 (0.14,0.72) 0.006 0.53 (0.21,1.31) 0.170 1.57 (0.49,4.99) 0.447 0.94 (0.27,3.27) 0.927
Serotype 19A (NVT) 2.5-,5 0.81 (0.22,2.90) 0.742 1.62 (0.30,8.65) 0.574 Infinite (---)a 0.161 0.16 (0.04,0.67) 0.013
5-,15 2.37 (0.76,7.32) 0.135 4.40 (0.86,22.42) 0.074 Infinite (---)a 0.003 0.79 (0.26,2.37) 0.677
.= 15 0.00 (0.00,2.18) 0.319 0 (0., ---) 1.000 0 (0, ---) 1.000 0 (0, ---) 0.229
All ages 1.28 (0.58,2.82) 0.542 2.393 (0.82,6.99) 0.111 11.50 (1.47,89.83) 0.020 0.41 (0.18,0.93) 0.033
aIt was not possible to fit the model. OR’s were calculated ignoring clustering and p-values using Fisher’s exact test.
bValues could not be calculated.
doi:10.1371/journal.pone.0072198.t004
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Serotype 6A, not included in PCV-7 but with potential cross-
protection from 6B polysaccharide and thus included in the VT
grouping, was the most prevalent VT. Although the study lacked
power for individual serotypes comparison, prevalence of serotype
6A was a lower (not statistically significant), in wholly vaccinated
villages. The time-trend analysis showed that the decrease of this
serotype after vaccination was slower in partly vaccinated villages
than for other VT, suggesting that cross-protection of serotype 6A
with serotype 6B was incomplete. This finding is in agreement
with the observation of a smaller decline in the incidence of
invasive pneumococcal disease caused by serotype 6A pneumo-
cocci compared to serotype 6B pneumococci following PCV-7
vaccination [23] and by the fact that PCV-7 can generate
functional 6A antibody but only for two thirds of the samples
tested [24]. In our study, serotype 6A was three times more
prevalent among VT isolates in CSS-4 compared to the baseline
survey. Genotyping of serotype 6A isolates showed high clonal
dissemination of 6A genotypes both before and after vaccination
with most new genotypes being encountered after vaccine
introduction. No serotype 6C isolate was detected and so far,
serotype 6C does not seem to have a strong presence in the region.
If we would have excluded serotype 6A from the VT group
analysis, differences between study arms in CSS-4 would have
increased.
Prevalence of NVT was similar in wholly vaccinated and partly
vaccinated villages more than 4 years after vaccination, indicating
that replacement has not been favored by the increased vaccine
pressure in wholly versus partly vaccinated villages. No increase in
the overall prevalence of NVT carriage was observed in either
study group during CSS-4 when compared to the baseline CSS,
indeed there was a decrease in some age groups. This was an
unexpected finding to which we do not have any satisfactory
explanation. However, it is a finding which is robust as the
methodologies used for sample collection, storage and laboratory
testing were similar between the pre-vaccination and post-
vaccination surveys and quality controls were in place throughout
the study. It cannot be attributed to any health intervention by the
study field team which had left the study villages more than two
years prior to conducting CSS-4. The mass azithromycin
treatment campaigns undertaken in some study villages more
Table 5. Distribution of Sequence Types (ST) of 55 serotype 6A pneumococcal isolates randomly selected from the different CSS
surveys.
ST Allelic profile Study CSS
Aroe gdh gki recP spi xpt ddl Baseline CSS-1 CSS-2 CSS-4 Total
913 6 57 83 28 7 19 9 2 2 0 4 8
1737 6 57 34 28 6 1 9 2 2 2 1 7
3324 7 8 1 5 42 60 14 5 0 0 1 6
919 16 38 4 16 7 358 28 2 1 1 0 4
5734 7 25 29 2 27 122 122 1 1 1 1 4
1288 60 82 1 4 42 122 28 0 0 2 1 3
4036 16 214 4 18 15 1 31 1 1 0 0 2
5716 16 214 4 18 15 4 31 1 0 0 1 2
8045* 7 57 83 28 7 19 14 0 1 1 0 2
912 6 57 34 28 7 1 9 0 1 0 0 1
3407 23 189 4 12 43 4 74 0 0 0 1 1
5527 1 25 4 4 6 122 28 0 0 0 1 1
5702 2 8 9 10 17 83 6 0 0 1 0 1
8039* 7 57 83 28 7 19 9 1 0 0 0 1
8040* 6 57 29 2 6 112 9 1 0 0 0 1
8041* 7 57 29 1 27 1 74 0 1 0 0 1
8042* 6 57 29 28 7 1 9 0 1 0 0 1
8043* 6 8 1 28 7 16 14 0 1 0 0 1
8044* 6 57 4 28 6 358 28 0 1 0 0 1
8046* 6 57 34 5 6 1 9 0 1 0 0 1
8047* 6 10 29 1 7 122 74 0 1 0 0 1
8048* 60 82 1 1 42 21 28 0 0 1 0 1
8049* 2 8 9 10 17 3 6 0 0 1 0 1
8050* 54 5 4 4 2 142 269 0 0 1 0 1
8053* 8 5 36 3 7 1 6 0 0 0 1 1
8054* 2 8 4 41 15 4 31 0 0 0 1 1
Total 16 15 11 13 55
*New Sequence Types described in this study. For the 13 new ST in the post-vaccination period, 7 come from samples collected in vaccinated villages and 6 from
control villages (2 of them from PCV-7 vaccinated children).
doi:10.1371/journal.pone.0072198.t005
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than two years before the last survey and in some surrounding
villages 3–4 months before CSS-4 was conducted might have
altered the transmission patterns in the area, as mingling between
the populations of different villages does occur but this seems
unlikely. Furthermore, azithromycin mass treatment campaigns
tend to have a short term effect on nasopharyngeal carriage of
pneumococci [25,26]. No other changes in antibiotic policy
occurred during the study period. Thus, we are left with the
assumption there has been some secular trend in the pattern of
pneumococcal transmission occurring during the course of the
study that was independent of vaccination which we have not been
able to characterise. Data from Upper River Region, The Gambia
has also shown a trend for a decrease in pneumococcal carriage in
children unrelated to vaccination [27]. This observed decrease in
both VT and NVT led to a decrease in the overall prevalence of
pneumococcal carriage in the study area.
A reassuring finding was that the overall prevalence of serotype
19A, an important cause of serotype replacement in many
geographical areas [2,3,10,13,28], did not increase following
vaccination, although there was an increase in the proportion of
NVT isolates due to this serotype, and the prevalence of carriage
with this serotype was no higher in wholly vaccinated than in
partly vaccinated villages. In addition, genotyping data showed
that all genotype 19A clustered with the presumed founder ST847
which was the most prevalent throughout the study, suggesting a
stable population. It has been speculated that serotype 19A
replacement is driven by antibiotic selection pressure [10],
although recent data from Norway have shown that replacement
of serotype 19A, at least in the case of invasive disease, can occur
in the absence of penicillin resistance [28]. In our study, high level
penicillin resistance was not detected although a higher prevalence
of intermediate resistance was observed in the last study CSS.
Sustained monitoring of this serotype is warranted as proportion-
ally it had become the most prevalent of all NVT isolates during
CSS-4.
A community trial conducted over a period of 7 years faces
challenges, some of which could have influenced the findings
reported in this paper. As discussed above, socio-economic
changes may have happened in the community over this long
time period which have not been recognized by the investigators.
Furthermore, a potential impact of seasonality on pneumococcal
carriage was not considered during the design of the initial study.
However, CSS-4 was undertaken at the end of the rainy season as
was the case for the initial baseline study.
Despite the challenges considered above, we have shown that
the decrease of VT carriage among Gambian villagers observed
shortly after vaccination continued for a further four years and the
herd effect resulting from vaccination of young children was
sustained. However, there is a trend towers lower prevalence of
VT prevalence as a result of vaccinating older children and adults.
Furthermore the prevalence of NVT, including that of serotype
19A, has not increased. A few months after the completion of
CSS-4, PCV-13, which contains conjugates representing most of
the current nasopharyngeal carriage prevalent serotypes in the
study area, replaced PCV-7 in the Gambian EPI programme. The
effect of this new vaccine on nasopharyngeal carriage of
pneumococci in these communities will be monitored.
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